DOSIsoft, SA, a leading provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear medicine, is proud to announce that its latest product release, PLANET® Onco Dose version 3.2 – multi-radionuclide, personalized, voxel-based dosimetry platform for both SIRT and MRT – received Medical Device Regulation (MDR) CE Mark on February 17, 2025, under the new (EU) Regulation 2017/745.

Now available for clinical use across Europe, this advanced software version enhances system openness and flexibility. It allows clinics to cover a broader range of therapies by supporting dose computation for isotopes such as 90Y, ¹⁷⁷Lu ¹⁶⁶Ho and ¹³¹I, with the possibility to incorporate others to meet evolving clinical needs. Additionally, clinics can benefit from optimized dosimetry workflows, including the single-time point workflow - reducing workload, enhancing patient comfort, streamlining clinical processes while ensuring reliable accuracy.

PLANET® Onco Dose: All-in-one dosimetry solution dedicated to patient-specific Theranostics
End-to-end, versatile, and vendor-neutral, the novel PLANET® platform is specially designed to integrate multi-radionuclide approaches, implement multi-workflow solutions, and support multi-therapy applications. Clinically validated, its product features - spanning patient diagnostics, treatment planning, and disease follow-up - enable highly personalized treatment for each patient.

- Multi-radionuclide: Already supporting 90Y resin & glass microspheres and ¹⁷⁷Lu, the solution now includes two additional radionuclides, ¹⁶⁶Ho and ¹³¹I, with the flexibility to integrate further beta- and gamma-emitting isotopes under the same certification.

- Multi-workflow: Designed to seamlessly integrate into existing clinical workflows, PLANET® Onco Dose supports both SIRT (Selective Internal Radiation Therapy) and MRT (Molecular Radiation Therapy) dosimetry, covering full 3D and 2D/3D hybrid methods for multi-timepoint workflows, as well as the newly introduced single-timepoint workflow – using a single imaging acquisition to improve workflow efficiency.

- Multi-therapy: The platform is suited for a variety of treatments, including ¹⁷⁷Lu-PSMA (prostate-specific membrane antigen) therapy, ¹⁷⁷Lu-PRRT (peptide receptor radionuclide therapy) for neuroendocrine tumors, 90Y or¹⁶⁶Ho radioembolization, ¹³¹I-mIBG for neuroblastoma, radioiodine treatment for hyperthyroidism and thyroid cancer, and more.

Additionally,PLANET® Onco Dose version 3.2 runs on a new operating system with long-term and cybersecurity support, ensuring compatibility with the latest workstation generations. The new release also benefits from GPU acceleration to delivering significantly enhanced performance, compared to previous versions.

Products and Clearances Homepage